Engflag

Tabilon

Quick links to important sections

Tabilon

Tabilon_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tabilon

Quick Facts

Property Description
Active ingredient Furosemide
Form Tablets, Oral solutions, Injectable solutions
Pharmacological class Loop diuretic / Saluretic
Common use Relieving fluid retention (edema)
Origin Synthetic compound

What is Tabilon?

Tabilon is a synthetic, prescription-only medicine whose active component is the compound Furosemide. It is fundamentally classified as a loop diuretic, a type of medication used to manage the body's fluid balance. Furosemide functions by increasing the excretion of water from the body.

Furosemide is recognized within the pharmacological domain as a high-ceiling diuretic due to its significant and robust capacity to promote diuresis. This potent action is clinically recognized for rapidly reducing excess fluid. Unlike milder diuretic classes, Furosemide's effect is known for its rapid onset, which is a distinctive factor in critical fluid management scenarios. The drug is a single-ingredient product, containing only Furosemide alongside necessary inactive excipients.

Tabilon's Composition and General Purpose

The active ingredient, Furosemide, acts directly on the kidneys, increasing the excretion of salts—specifically sodium and chloride—which subsequently promotes the loss of water. The general purpose of Tabilon is to relieve fluid retention, also known as edema, or conditions involving systemic volume overload.

Tabilon is supplied in various pharmaceutical preparations, including solid tablets for oral use and sterile injectable solutions for parenteral administration. Furosemide acts primarily to increase the removal of salt and water through the kidneys. This targeted salt and water excretion is the core physiological action that underpins its use against swelling and excess fluid, a function crucial for maintaining proper fluid homeostasis.

What side effects are possible with Tabilon?

Possible Side Effects and Safety Information

The regulatory profile for Tabilon (Furosemide) centers on adverse reactions related to its function as a potent loop diuretic, primarily involving fluid and electrolyte balance.

Frequency-Classified Adverse Reactions

Adverse effects are classified according to frequency in official regulatory documents:

  • Very Common: Disturbances of fluid and electrolyte balance, including Hypokalaemia (low potassium) and Hypovolaemia (reduced blood volume), which may lead to dehydration.
  • Common: Symptomatic Hypotension (low blood pressure causing symptoms) and increases in blood creatinine and urea.
  • Uncommon: Hearing impairment and deafness (which can be irreversible), as well as photosensitivity reactions affecting the skin.
  • Rare: Tinnitus, severe anaphylactic reactions (severe allergic responses), and certain blood cell disorders.

These effects are categorized across several System-Organ Classes, including Metabolism and Nutrition, Vascular, Ear and Labyrinth, and Renal disorders.

Serious Safety Considerations

Official labeling documents certain serious adverse reactions. These include the potential for hepatic encephalopathy in patients with pre-existing severe liver impairment. The risk of deafness and severe anaphylactic reactions are also officially documented. Due to Furosemide being a sulfonamide derivative, cross-sensitivity with other sulfonamide-derived medicines is a regulatory consideration.

Population-Specific Safety Notes

Regulatory documents include specific safety statements for certain groups. Older adults face an increased risk of dehydration and thrombosis/embolism due to significant volume reduction. For patients with hepatic insufficiency, there is a heightened, documented risk of rapidly developing hepatic encephalopathy if fluid and electrolyte balance is disturbed.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Tabilon (Furosemide) may result in severe physiological manifestations that require immediate medical attention. The official overdose profile is defined by an extreme extension of the drug's intended action, leading to profound diuresis and rapid water and electrolyte depletion.

Documented Overdose Presentations

Overdose presentations include severe dehydration, hypotension (low blood pressure), drowsiness, weakness, and muscle cramps resulting from critical imbalances such as hypokalemia and hyponatremia. The most serious outcomes documented in regulatory labeling are circulatory collapse, which can lead to vascular thrombosis and embolism. In patients with pre-existing liver disease, overdose may precipitate hepatic encephalopathy or coma.

Required Emergency Action

Urgent medical help must be sought immediately if the affected person shows signs of collapse, experiences a seizure, has trouble breathing, or cannot be awakened. Overdosage necessitates careful medical supervision and the frequent determination of serum electrolytes and blood pressure.

Management is supportive as no specific antidote is known. The official guidance emphasizes the priority of replacing excessive fluid and electrolyte losses to stabilize the patient’s condition. Elderly patients and those with hepatic cirrhosis face documented higher risks of severe complications.

Therapeutic Uses of Tabilon

What Tabilon Treats: Main Uses and Benefits

Tabilon (Furosemide) is used for managing specific clinical situations where the body retains too much fluid and salt, directly addressing the resulting symptoms and discomfort.

Furosemide is commonly used to treat edema (excess fluid held in body tissues) caused by various medical problems, including heart failure, liver disease, and kidney disease.

Easing Systemic Fluid Overload and Congestion

This medication is commonly used to address conditions marked by significant fluid retention, which manifests as uncomfortable swelling in the legs, ankles, or abdomen. It provides the key therapeutic benefit of assisting in the mobilization of accumulated fluid, thereby reducing the physical burden of swelling and supporting a more manageable state of fluid balance. Tabilon is considered relevant in clinical contexts where congestion causes symptoms such as shortness of breath or volume-related high blood pressure, offering symptomatic support for conditions including Congestive Heart Failure and liver cirrhosis.

Quick Fact: Management of Systemic Fluid Overload

Therapeutic Focus Primary Symptom Management
Congestion Easing shortness of breath and fluid accumulation
Volume Control Assisting in the management of volume-related hypertension
Chronic Support Providing relief in conditions involving chronic fluid imbalance

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Tabilon?

Tabilon (Furosemide) eligibility is strictly defined by regulatory documents, focusing on patient status and specific conditions where use is contraindicated or requires restriction. The medicine is generally established for use in adults and pediatric patients for labeled indications.

Absolute Contraindications

Tabilon must not be used by patients who have an absolute contraindication, as documented in official labeling:

  • Anuria (complete lack of urine production).
  • Known Hypersensitivity to Furosemide or sulfonamide-derived medicines.
  • Hepatic Coma and Pre-Comatose States.
  • Severe Hypovolemia (dehydration) or Severe Electrolyte Depletion.

Restricted and Special Populations

Specific patient groups require mandated caution or their use status is formally restricted:

Population Group Regulatory Status
Pregnancy Restricted use; permitted only if the potential benefit justifies the potential risk to the fetus.
Lactation Contraindicated or Not Recommended as the medicine is excreted into breast milk.
Premature Infants Requires caution and close monitoring due to specific renal risks.
Older Adults Use is permitted but requires close supervision due to increased sensitivity to adverse effects.

These constraints define the official eligibility profile and ensure use aligns strictly with governmental authorization.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tabilon (Furosemide) has several formally documented interaction patterns that are described in official regulatory labeling. These interactions primarily involve pharmacodynamic effects, such as the potentiation of toxicity or additive effects on blood pressure and electrolytes, as well as pharmacokinetic changes to drug clearance.

Official Regulatory Restrictions

Co-administration is generally restricted or discouraged with certain substances due to documented risks:

  • Ethacrynic Acid: Must be avoided due to the high risk of additive ototoxicity (hearing damage).
  • Lithium: Co-administration is discouraged as Furosemide reduces its renal clearance, leading to a significant risk of Lithium toxicity (increased exposure).
  • Aminoglycoside Antibiotics (e.g., Gentamicin): Use must be avoided due to the potential for enhanced ototoxicity, a risk that is particularly severe in the context of renal impairment.

Pharmacodynamic and Exposure-Modifying Interactions

Interacting Agent/Category Officially Documented Effect
ACE Inhibitors or ARBs Risk of severe hypotension and potential deterioration of renal function due to an additive blood pressure lowering effect.
Corticosteroids Risk of additive hypokalemic effects (increased potassium loss).
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) May cause a reduction in the diuretic effect of Furosemide.
Sucralfate Requires at least two hours of administration separation as it reduces Furosemide's effect.
Alcohol, Barbiturates, or Narcotics May potentiate the effects of orthostatic hypotension.

Excessive dietary salt intake is noted to directly counteract the drug's core action, which reduces the intended natriuretic efficacy.

Mechanism of Action

How Tabilon Works

Targeted Inhibition of Renal Salt Reabsorption

Tabilon's mechanism is defined by its action as a competitive inhibitor of the Na^+- K^+-2 Cl^- Symporter ( NKCC2), a protein located in the kidney's thick ascending limb. By directly blocking this transporter, the drug prevents the major reabsorption of sodium, potassium, and chloride ions from the tubular fluid back into the bloodstream, which initiates the molecular action.

Pathway of Osmotic Disruption and Fluid Mobilization

The failure to reabsorb these key electrolytes impairs the kidney's ability to create and maintain the medullary osmotic gradient—the natural mechanism used to conserve water. This disruption ensures that a high solute concentration remains within the urine-forming tubule, resulting in substantial suppression of passive water reabsorption downstream. This cascade leads to a rapid increase in the excretion of both electrolytes and water, causing a decrease in the body's extracellular fluid volume.

Constraints on Active Mechanism Delivery

The effectiveness of the mechanism is fundamentally dependent on the active substance reaching the NKCC2 target via a process of active tubular secretion in the kidney. This reliance on tubular secretion means that the efficiency of the mechanism is limited by the functional capacity of the kidney to deliver Furosemide to the luminal side.

Dosage and Administration Information

The administration of Tabilon (Furosemide) is guided by strict parameters that define its use based on the patient's condition and route of intake. The medicine is supplied in oral dosage forms (tablets and solutions) for maintenance and routine use, and as a sterile injectable solution for intravenous (IV) or intramuscular (IM) administration, primarily in acute or urgent clinical settings.

The standard oral dosing regimen typically begins with 20 mg to 80 mg taken once daily. The dose is then adjusted, often in increments of 20 mg to 40 mg, no sooner than 6 to 8 hours following the previous dose. This titration establishes a stable maintenance schedule, which may involve once or twice daily dosing, ensuring the medicine is not taken too late in the day to avoid sleep disruption. For severe edematous states, the maximum labeled daily oral dose is up to 600 mg.

Parenteral administration requires specific procedural constraints. The IV injection must be administered slowly over 1 to 2 minutes; in the event of an infusion, the rate must not exceed 4 mg per minute. Initial IV doses range from 20 mg to 40 mg, with adjustments permitted after a minimum interval of 2 hours. As a standard practice, patients are transitioned from parenteral to oral therapy as soon as their clinical status allows. For older adults, the initial dose must be cautiously selected, typically starting at the low end of the dosing range, a principle also applied to weight-based dosing for pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tabilon (Furosemide)

Evidence for Fluid Retention Associated with Heart Failure (Edema)

Research exploring Tabilon’s use for fluid retention linked to heart conditions primarily consists of Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies were studied for adult and older adult populations and examined its use in managing fluid retention and congestion. Researchers monitored changes in outcomes related to systemic or functional imbalance, such as body weight and urine output, and also used in research exploring how symptoms change over time.

Studies consistently reported measurements of increased urinary output and measurements of fluid change in the observed populations. Trials described patterns such as fluid mobilization, and reported measurements of reductions in physical swelling and body weight over defined time intervals. This research provides insight into short-term changes in fluid status. Long-term data regarding major chronic outcomes are not fully established. Research is still exploring the consistency of the response for continuous, long-term use.

Evidence for Fluid Retention in Liver Disease and Cirrhosis (Ascites)

The body of research for fluid retention, or ascites, associated with liver cirrhosis typically involves RCTs and comparative trials where Tabilon was evaluated in combination with other types of diuretics. Researchers focused on outcomes related to functional imbalance, specifically outcomes related to ascites and changes in abdominal girth.

Trials frequently described patterns of significant fluid change and reported measurements of sodium excretion. The measured change in fluid status was observed in short-term studies. However, the effectiveness of Tabilon's action as a stand-alone therapy for ascites is not well-characterized, as the majority of research has studies monitored its use as part of a combination regimen.

Research Gaps and Areas of Uncertainty

Key areas where research remains sparse or the evidence is limited include:

  • Comparative evidence is lacking in large-scale modern trials that assess Tabilon's action directly against many newer therapies available today.
  • Data for certain groups remain insufficient, particularly in specific pediatric age groups and in patients where fluid retention is complicated by severe, co-existing health conditions.
  • Evidence quality varies across studies depending on the specific patient subgroup and the duration of follow-up. This variability means that certainty remains low in some areas of practice.

Key Studies & References Efficacy of furosemide in patients with chronic kidney disease with residual renal functions in hemodialysis and non-hemodialysis

Frequently Asked Questions (FAQ)

Common questions about Tabilon (FAQ)

Q: Can I stop taking it suddenly, or do I need to taper off?

Regulatory information for many medications may include warnings about the potential risks of withdrawal effects or symptom recurrence if treatment is stopped abruptly. Official prescribing information may specify that the dose should be gradually reduced, or tapered, when discontinuing the medication. These documents describe the proper procedure for cessation as determined by the regulatory authority.

Q: Is it safe for kidney patients?

Official drug labeling addresses the use of Tabilon in patients with impaired kidney function (renal impairment). The product information may specify criteria for dose reduction in cases of impaired kidney function. In severe kidney disease, regulatory documents may state that the medication is contraindicated or should not be used, based on the drug's properties.

Q: Can I take it while breastfeeding?

Official information for Tabilon includes details on use during lactation. Regulatory documents state whether the drug or its components pass into human milk and if a nursing infant may be exposed. This information indicates whether the medication is contraindicated or if caution is advised during breastfeeding, based on available data.

Q: Does it interact with grapefruit juice?

Regulatory documents list known interactions between the drug and other substances, including certain foods. If an interaction with grapefruit or grapefruit juice exists, the official product information generally advises against or recommends caution with the consumption of grapefruit products while taking Tabilon.

How should Tabilon be stored and disposed of?

How to Store and Dispose of Tabilon

The following is a summary of the official storage and disposal requirements for Tabilon (Tibolone) as documented in regulatory labeling.

Official Storage Requirements

Condition Requirement
Temperature No special temperature storage conditions are required.
Protection Must be stored in the original package to protect from light and moisture.
Handling Keep in the original container.
Shelf Life The unopened product has a shelf life of 3 years.

Disposal Instructions

Regulatory documents mandate that any unused medicinal product or waste material be disposed of in accordance with local requirements. Disposal must be performed in compliance with local environmental and pharmaceutical-waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tabilon found in:

A-Z Index: